Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

YTEN - Yield10 Bioscience

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Dan Thunderbolt, Apr 19, 2018.

  1. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
  2. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    To fulfill biofuels’ promise, scientists boost plant oils with gene editing
    November 25, 2018
    https://cen.acs.org/energy/biofuels/fulfill-biofuelspromise-scientists-boost-plant/96/i47

    ...
    To Peoples, the future looks promising. A 20% increase in the yield of conventional oil crops like canola and soybean could boost the economic value of these crops by $10 billion, he says. If the current techniques work well in camelina, the company will attempt similar gene edits in canola and soybeans.

    Although Yield10’s primary goal is to sell its camelina oil for human health products and as an ingredient for agricultural animal feed rather than as a feedstock for biofuels, Peoples says the gene-editing discovery made by Yield10 could be beneficial for that type of application too.

    Yield10 won’t disclose the exact edits its scientists made to improve camelina’s oil production, citing proprietary information. But presentation slides shared online on Nov. 4 for investors indicate that edits to genes that the firm calls C3008a, C3008b, and C3009 work to increase oil production by simultaneously increasing fatty acid biosynthesis and blocking the metabolism of the synthesized lipid.

    At the same time, Yield10’s Canadian subsidiary, Metabolix Oilseeds, is working to edit a gene the company has called C3007 in camelina and canola. Gene C3007 encodes a protein that negatively regulates a key enzyme in fatty acid biosynthesis, acetyl-CoA carboxylase. By decreasing the activity of this negative regulator, the firm aims to boost the enzyme’s activity and make more plant oil.
    ...
     
  3. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
  4. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    Increasing Crop Yield Through Smart Approaches In Trait Discovery
    December 3, 2018
    https://sciencetrends.com/increasing-crop-yield-through-smart-approaches-in-trait-discovery/

    In Yield10’s research, the use of these models from the perspective of the company’s trait discovery and development program are detailed extensively, and one day may make significant impacts on the cost and timeline for developing new yield traits for major row crops – all of which could help in the challenge of addressing global food security challenges.
     
  5. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
  6. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    Dec 13, 2018


    Yield10 Bioscience Names Sherri M. Brown, Ph.D., Former Monsanto Executive, as Special Commercial and Technical Advisor

    WOBURN, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today named Sherri M. Brown, Ph.D., as a special commercial and technical advisor to the Company, effective immediately. Dr. Brown is currently managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in a number of leadership positions involving the development and global commercialization of new biotechnology traits for canola, soybean and corn at Monsanto Company for 28 years.

    https://yield10bioscienceinc.gcs-we...ence-names-sherri-m-brown-phd-former-monsanto
     
  7. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
  8. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    Yield10 Bioscience (YTEN) Now Covered by National Securities
    Jan 25th, 2019
    https://www.modernreaders.com/news/...-yten-now-covered-by-national-securities.html

    Yield10 Bioscience logoInvestment analysts at National Securities initiated coverage on shares of Yield10 Bioscience (NASDAQ:YTEN) in a report issued on Wednesday, The Fly reports. The brokerage set a “buy” rating and a $5.00 price target on the specialty chemicals company’s stock.

    Commercial Relationships In Early Stages. Since late 2017, two research license agreements have been reached with Monsanto and Forage Genetics International, major players in the soybean and sorghum markets, respectively. While these are research agreements for now, we believe these announcements validate Yield10’s technology and represent the kind of relationships that could generate commercial revenue.

    High Ceiling Value. Between the value of the IP portfolio in the near term, and the potential value provided by commercial revenue streams, we believe shares of Yield10 could prove to be materially undervalued at current levels. Should commercialization agreements materialize, we believe our twelve month price target could prove to be conservative.”
     
  9. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
  10. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
  11. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    Nice gain today.
     
  12. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    Aug 12, 2019


    Yield10 Bioscience Announces Notice of Allowance for U.S. Patent Covering Crop Yield Trait C4001

    WOBURN, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office allowing its patent application covering the use of C4001 to improve productivity in crops.
    https://yield10bioscienceinc.gcs-we...cience-announces-notice-allowance-us-patent-0
     
  13. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    In the past few weeks I bought some YTEN shares again. I am hoping for some good news in next few months.

    Aug. 12, 2019
    Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2019 Results - Earnings Call Transcript
    https://seekingalpha.com/article/42...ples-q2-2019-results-earnings-call-transcript

    “CBD is a good example of a product targets for Yield10's traits and capabilities that considerable value for third-party with deep knowledge of the medical CBD business. Yet we're seeing a funded R&D program and upfront payments research funding and license revenues, as appropriate. These product targets provide opportunities for Yield10 to develop businesses that generate product revenue and/or partnerships of downstream revenue. We will keep you posted as it continues to make progress and finalize the business cases.

    “And we're also actively engaged in discussions with third parties interested in deploying our traits in a variety of other commercially important crops. We plan to keep you updated on the progress we're making all of these areas in the second half 2019.
     
  14. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    Interesting items raised in the National Research report.

    Yield10 Bioscience’s (NASDAQ:YTEN) Buy Rating Reiterated at National Securities
    Thursday, September 12th, 2019
    Lars Charter
    https://rivertonroll.com/news/2019/...ives-buy-rating-from-national-securities.html

    The firm currently has a $5.00 price target on the specialty chemicals company’s stock.

    • Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR – €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes.

      A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology.

      No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market.

      Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component.,” National Securities’ analyst wrote.
     
  15. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    285
    Likes Received:
    27
    Besides their cooperation with Bayer/Monsanto, YTEN has also granted a Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum. Forage Genetics is a subsidiary of Land O’Lakes, Inc. According to Wikipedia the annual revenue of Land O’Lakes is $15 Billion. Hopefully there is more to come.

    Link: http://ir.yield10bio.com/node/14091/pdf
     

Share This Page